PARAGARD T380A Rx
Generic Name and Formulations:
Copper-bearing intrauterine contraceptive device.
The Cooper Companies
Indications for PARAGARD T380A:
See literature. ≥16yrs: Insert into uterine cavity. Check placement shortly after first menses. Replace at least every 10 years.
<16yrs: not recommended.
Uterine abnormality. Uterine or cervical malignancy. Pelvic inflammatory disease or risk thereof. Postpartum or postabortal endometritis in the past 3 months. Genital actinomycosis. Abnormal genital bleeding. Cervicitis. Wilson's disease. Retained IUD. Pregnancy or suspicion of pregnancy.
Vaginal bleeding. Ectopic pregnancy. Immunocompromised. Immunosuppressive therapy. Avoid medical diathermy. Assure suitable uterine anatomy before insertion. Remove the device if evidence of partial expulsion, perforation, or breakage.
Bleeding, cramps, anemia, dyspareunia, pelvic infection, infertility, ectopic pregnancy, uterine or cervical perforation, embedment or fragmentation of device, septicemia (during pregnancy), spontaneous abortion, vasovagal reactions (during insertion or removal).
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Patient-Reported Outcomes in Oncology Expected to Make Regulatory Waves
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- FDA Provides Update on Breast Implant-Associated Anaplastic Large Cell Lymphoma
- Q&A With Mark B. Gerstein, PhD, on Diagnostic Genomic vs Exomic Sequencing
- Immune Signature for Renal Cell Papillary Carcinoma Predicts Outcome
- Nivolumab-Ipilimumab Survival Benefit in Advanced RCC Confirmed
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Adding Chemotherapy to Radiation Post-Radical Cystectomy Improves Survival in Urothelial Carcinoma
- Radiation, Chemotherapy Not Beneficial in Localized Upper Tract Urothelial Carcinoma
- Radical Cystectomy Superior to Trimodal Therapy for Muscle-Invasive Bladder Cancer